Approximately half of the patients with signs and symptoms of heart failure have a left
ventricular ejection fraction that is not markedly abnormal. Despite the historically initial …

This review aims to provide a translational perspective on recent developments in heart
failure with preserved ejection fraction (HFpEF), linking mechanistic insights to potential …

There is an unmet need for effective treatment strategies to reduce morbidity and mortality in
patients with heart failure with preserved ejection fraction (HFpEF). Until recently, attention in …

Objectives: The present study investigated whether systemic, low-grade inflammation of
metabolic risk contributed to diastolic left ventricular (LV) dysfunction and heart failure with …

Aims Right ventricular (RV) dysfunction and pulmonary hypertension (PH) are increasingly
recognized in heart failure with preserved ejection fraction (HFpEF). The prevalence and …

Heart failure (HF) is a complex syndrome that affects approximately 6.5 million adults in the
United States. About half of the 6.5 million adults with HF are estimated to be individuals with …

Aims Pulmonary hypertension (PH) and pulmonary vascular disease (PVD) are common
and associated with adverse outcomes in heart failure with preserved ejection fraction …

Chronic heart failure (CHF) is a complex syndrome that results from structural and functional
disturbances that affect the ability of the heart to supply oxygen to tissues. It largely affects …

The complex physiological signal transduction networks that respond to the dual challenges
of inflammatory and oxidative stress are major factors that promote the development of …

Heart failure (HF) is an important global health problem with great socioeconomic burden.
Outcomes remain sub-optimal. Endothelium–cardiomyocyte interactions play essential roles …